Abstract
Background: In boron neutron capture therapy (BNCT), the intravenous administration of boron-containing compounds such as boronophenylalanine (BPA) and borocaptate sodium (BSH) is followed by irradiation with thermal neutrons. In the present study, we determined whether a boron-rich boron carbide (B4C) nanoparticle could be used for BNCT. Methods: B4C nanoparticles were obtained by the laser fragmentation of boron particles in ethyl acetate. Neutron irradiation was delivered via a neutron beam at the Kyoto University Research Reactor (KUR). Results: Cell viability was lower in oral squamous cell carcinoma (SCC) cells exposed to neutrons in the presence of B4C particles than in those exposed to neutrons only. The combination of B4C particles and neutron irradiation also decreased the formation of colonies.Injecting B4C particles into the oral SCC xenografts of nude mice increased the concentration of 10B in the tumors, but not in the kidney, liver, or spleen. The body weights of animals were not affected by neutron irradiation to B4C-injected tumors.Tumor volumes were lowerTumor volumes were lower in the B4C- mediated BNCT group than in the neutron group. Conclusion: These results indicate that B4C particles can be used locally as a boron compound in BNCT for oral SCC.
Highlights
Boron neutron capture therapy (BNCT) is a binary modality, in which the intravenous administration of boron-containing compounds is followed by irradiation with thermal neutrons. 10B in tumors absorbs a thermal neutron and releases two high linear energy transfer (LET) particles: an α(4He) particle and lithium (7Li) nucleus
When cells were incubated with B4C particles for 10 min and exposed to neutrons in the presence of B4C particles, cell viability was decreased to 77% of the control 48 h after the treatment (Figure 1)
When the surviving cell fraction was measured from the formation of colonies after neutron irradiation and B4C-mediated boron neutron capture therapy (BNCT), the number of colonies was decreased to 79% and 38 % of the untreated control, respectively (Figure 2)
Summary
Boron neutron capture therapy (BNCT) is a binary modality, in which the intravenous administration of boron-containing compounds is followed by irradiation with thermal neutrons. 10B in tumors absorbs a thermal neutron and releases two high linear energy transfer (LET) particles: an α(4He) particle and lithium (7Li) nucleus. Boron neutron capture therapy (BNCT) is a binary modality, in which the intravenous administration of boron-containing compounds is followed by irradiation with thermal neutrons. A difficult expression of LAT-1 and arrest of the cell cycle may be responsible for the failed incorporation of BPA into tumor cells. These compounds contain a small amount of boron within their molecules. In boron neutron capture therapy (BNCT), the intravenous administration of boron-containing compounds such as boronophenylalanine (BPA) and borocaptate sodium (BSH) is followed by irradiation with thermal neutrons. We determined whether a boron-rich boron carbide (B4C) nanoparticle could be used for BNCT
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Nuclear Medicine & Radiation Therapy
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
